NCT07046221 2025-07-20Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or SurgeryFujian Cancer HospitalPhase 2 Not yet recruiting60 enrolled
NCT05628610 2024-08-13Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal CancerFujian Cancer HospitalPhase 2 Not yet recruiting130 enrolled